Cambridge, UK and Indianapolis, US – 1 October 2019: Acacia Pharma Group plc (the “Company), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission in aggregate of 303,841 Ordinary Shares of £0.02 each (the “New Ordinary Shares”) to trading on Euronext Brussels (“Admission”) to satisfy the exercise of options granted under the Company’s Enterprise Management Incentive Share Option Plan. This includes options exercised by Dr Gabriel Fox (Chief Medical Officer and PDMR) to subscribe for 168,651 Ordinary Shares of £0.02 each in the Company at an exercise price of £0.15 each.
Following the exercise of these options, Dr Fox holds 497,227 Ordinary Shares, representing approximately 0.92% of the Company’s enlarged issued share capital. Dr Fox holds 52,631 of these shares through Comedica Consulting Limited, a company wholly owned by him.
The New Ordinary Shares will rank pari passu in all respects with the Company’s existing Ordinary Shares in issue.
Following issue of the New Ordinary Shares, the Company’s total issued share capital will consist of 53,938,756 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 53,938,756.
Acacia Pharma Group plc
Michael Bolinder, CEO
Christine Soden, CFO
+44 1223 919760
Citigate Dewe Rogerson
Mark Swallow, Shabnam Bashir, David Dible
+44 20 7638 9571